The drug did, however, significantly improve progression-free survival.
Encouraging activity noted in several tumor types.
Analysis of biomarkers to predict response to pembrolizumab are ongoing.
The TC model uses various parameters to predict risk such as genetic risk and nonfamilial factors including personal, hormonal, and lifestyle characteristics.
Overall survival data are not currently mature. However, at the time of this analysis no difference in overall survival was observed between the 3 treatment arms.
A longer treatment-free survival interval associated with surgery may contribute to overall survival.
The researchers found that patients who received pelvic radiation had a decreased chance of live birth.
A trial in progress will evaluate the combination of immunotherapy with tadalafil and vancomycin.
The phase 1b included 104 patients who received lenvatinib 12 mg per day or 8 mg per day plus pembrolizumab 200 mg on day 1 of a 21-day cycle.
Noninvasive method could help monitor treatment responses.
SBRT preserved quality of life and eliminated need for post-TACE hospitalization in patients with hepatocellular carcinoma.
The administration of apatinib in patients with advanced HCC led to improvements in survival with a manageable safety profile.
Early results warrant further exploration of intrahepatic injection of T-VEC, a genetically modified oncolytic HSV-1, in combination with pembrolizumab.
Though they are costly, broad genetic assays that look for many gene mutations at once may confer more value overall than a one-off testing approach for patients with nsNSCLC.
In the 3 ongoing responses, all had PD-L1–positive disease.
Irinotecan and temozolomide led to inferior clinical outcomes for patients with recurrent and primary refractory Ewing sarcoma, a multiarm trial found.
Overall, grade 3 to 4 AEs were noted in 33% of patients receiving the immunotherapy combination vs 36% of patients receiving chemotherapy.
A chemotherapy regimen that is standard in the US for patients with Ewing sarcoma appeared to improve outcomes, a randomized phase 3 trial showed.
Three of 9 patients with measurable central nervous system metastases had an intracranial complete response, with a 56% overall response rate in this subgroup.
Twenty-six (61.9%) patients had an ORR as confirmed by independent central review.